NIH Common Fund Data Ecosystem (CFDE) FAIR Rubric

A rubric for evaluating the FAIRness of NIH-CFDE Resources

Tags: nihcommonfund

URL(s):

View Associations

Rubric Assessments (626384)


Assessment Metrics Date
Target Project   Contact information is provided for the creator(s) of the dataset. Globally unique identifier Machine-readable metadata Standardized metadata Resource identifier in metadata Open, Free, Standardized Access protocol Digital resource license Metadata license NIH program name is available for querying NIH project name is available for querying The institution that created this dataset is available A biological assay is present and resolvable in CFDE-specified ontology (OBI) A relevant anatomical part is present and resolvable in the UBERON Ontology A relevant disease is present and resolvable in the MONDO Ontology A relevant file type is present and resolvable in the EDAM Ontology A relevant taxonomy is present and resolvable in the NCBITaxon Ontology A relevant cell line is present and resolvable in the Cellosaurus Ontology A landing page exists and is accessible
Aspirin Metabolomics in Colorectal Cancer Chemoprevention (part 1 - Colon) Metabolomics: FAIR Assessment of NIH Common Fund Resources with C2M2
no (0.00) no (0.00) yes (1.00)   yesbut (0.75) no (0.00) no (0.00) yes (1.00) no (0.00) yes (1.00) no (0.00) no (0.00) no (0.00) no (0.00) no (0.00) no (0.00) no (0.00) no (0.00) Sep 23, 2019
Natural genetic variation in C. elegans identified genomic loci controlling metabolite levels Metabolomics: FAIR Assessment of NIH Common Fund Resources with C2M2
maybe (0.50) no (0.00) yes (1.00)   yesbut (0.75) yes (1.00) no (0.00) yes (1.00) no (0.00) yes (1.00) yesbut (0.75) nobut (0.25) no (0.00) no (0.00) no (0.00) no (0.00) no (0.00) yes (1.00) Sep 23, 2019
Untargeted metabolomic profile of oak and wine yeast strains Metabolomics: FAIR Assessment of NIH Common Fund Resources with C2M2
maybe (0.50) no (0.00) yes (1.00)   yesbut (0.75) yes (1.00) no (0.00) yes (1.00) no (0.00) yes (1.00) yesbut (0.75) nobut (0.25) no (0.00) no (0.00) no (0.00) no (0.00) no (0.00) yes (1.00) Sep 23, 2019
Analysis of short chain phosphatidylcholine (PC) on the Golgi membrane Metabolomics: FAIR Assessment of NIH Common Fund Resources with C2M2
maybe (0.50) no (0.00) yes (1.00)   yesbut (0.75) yes (1.00) no (0.00) yes (1.00) no (0.00) yes (1.00) yesbut (0.75) nobut (0.25) no (0.00) no (0.00) no (0.00) no (0.00) no (0.00) yes (1.00) Sep 23, 2019
Progesterone level effects on primary metabolites in uterus, blood, and ovaries (Part 2:Uterine flush) Metabolomics: FAIR Assessment of NIH Common Fund Resources with C2M2
maybe (0.50) no (0.00) yes (1.00)   yesbut (0.75) yes (1.00) no (0.00) yes (1.00) no (0.00) yes (1.00) yesbut (0.75) nobut (0.25) no (0.00) no (0.00) no (0.00) no (0.00) no (0.00) yes (1.00) Sep 23, 2019
Kidney choline acetyltransferase (ChAT)-(part II) Metabolomics: FAIR Assessment of NIH Common Fund Resources with C2M2
maybe (0.50) no (0.00) yes (1.00)   yesbut (0.75) yes (1.00) no (0.00) yes (1.00) no (0.00) yes (1.00) yesbut (0.75) nobut (0.25) no (0.00) no (0.00) no (0.00) no (0.00) no (0.00) yes (1.00) Sep 23, 2019
Lipidomics in (SIDS) Sudden Infant Death Syndrome Metabolomics: FAIR Assessment of NIH Common Fund Resources with C2M2
maybe (0.50) no (0.00) yes (1.00)   yesbut (0.75) yes (1.00) no (0.00) yes (1.00) no (0.00) yes (1.00) yesbut (0.75) nobut (0.25) no (0.00) no (0.00) no (0.00) no (0.00) no (0.00) yes (1.00) Sep 23, 2019
Identification of altered metabolic pathways in Alzheimer's disease, mild cognitive impairment and cognitively normals using Metabolomics (plasma) Metabolomics: FAIR Assessment of NIH Common Fund Resources with C2M2
maybe (0.50) no (0.00) yes (1.00)   yesbut (0.75) yes (1.00) no (0.00) yes (1.00) no (0.00) yes (1.00) yesbut (0.75) nobut (0.25) no (0.00) no (0.00) no (0.00) no (0.00) no (0.00) yes (1.00) Sep 23, 2019
Targeted metabolomics data of leprosy patients with type 1 reaction Metabolomics: FAIR Assessment of NIH Common Fund Resources with C2M2
maybe (0.50) no (0.00) yes (1.00)   yesbut (0.75) yes (1.00) no (0.00) yes (1.00) no (0.00) yes (1.00) yesbut (0.75) nobut (0.25) no (0.00) no (0.00) no (0.00) no (0.00) no (0.00) yes (1.00) Sep 23, 2019
Large Untargeted Profiling of Myelin to Enhance Recovery of Function after SCI Metabolomics: FAIR Assessment of NIH Common Fund Resources with C2M2
no (0.00) no (0.00) yes (1.00)   yesbut (0.75) no (0.00) no (0.00) yes (1.00) no (0.00) yes (1.00) no (0.00) no (0.00) no (0.00) no (0.00) no (0.00) no (0.00) no (0.00) no (0.00) Sep 23, 2019
Metabolic analysis of Parp1 ko/wt Saline & Bleo Mouse Lung Fiboblasts and Human IPF & Normal Lung Fiboblasts (Part 2) Metabolomics: FAIR Assessment of NIH Common Fund Resources with C2M2
maybe (0.50) no (0.00) yes (1.00)   yesbut (0.75) yes (1.00) no (0.00) yes (1.00) no (0.00) yes (1.00) yesbut (0.75) nobut (0.25) no (0.00) no (0.00) no (0.00) no (0.00) no (0.00) yes (1.00) Sep 23, 2019
Activity-Based Metabolic Profiling of M. tuberculosis H37Rv Rv3801 Metabolomics: FAIR Assessment of NIH Common Fund Resources with C2M2
maybe (0.50) no (0.00) yes (1.00)   yesbut (0.75) yes (1.00) no (0.00) yes (1.00) no (0.00) yes (1.00) yesbut (0.75) nobut (0.25) no (0.00) no (0.00) no (0.00) no (0.00) no (0.00) yes (1.00) Sep 23, 2019
Insights into myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) phenotypes through comprehensive metabolomics (part IV) Metabolomics: FAIR Assessment of NIH Common Fund Resources with C2M2
maybe (0.50) no (0.00) yes (1.00)   yesbut (0.75) yes (1.00) no (0.00) yes (1.00) no (0.00) yes (1.00) yesbut (0.75) nobut (0.25) no (0.00) no (0.00) no (0.00) no (0.00) no (0.00) yes (1.00) Sep 23, 2019
Retinal ganglion cells lipid profiling Metabolomics: FAIR Assessment of NIH Common Fund Resources with C2M2
maybe (0.50) no (0.00) yes (1.00)   yesbut (0.75) yes (1.00) no (0.00) yes (1.00) no (0.00) yes (1.00) yesbut (0.75) nobut (0.25) no (0.00) no (0.00) no (0.00) no (0.00) no (0.00) yes (1.00) Sep 23, 2019
NEFA Panel in Serum for Muscle Wasting in Cancer Cachexia (part-VI) Metabolomics: FAIR Assessment of NIH Common Fund Resources with C2M2
no (0.00) no (0.00) yes (1.00)   yesbut (0.75) no (0.00) no (0.00) yes (1.00) no (0.00) yes (1.00) no (0.00) no (0.00) no (0.00) no (0.00) no (0.00) no (0.00) no (0.00) no (0.00) Sep 23, 2019
Amino Acid Concentrations in Muscle Tissue of Muscle Wasting in Cancer Cachexia (part I) Metabolomics: FAIR Assessment of NIH Common Fund Resources with C2M2
maybe (0.50) no (0.00) yes (1.00)   yesbut (0.75) yes (1.00) no (0.00) yes (1.00) no (0.00) yes (1.00) yesbut (0.75) nobut (0.25) no (0.00) no (0.00) no (0.00) no (0.00) no (0.00) yes (1.00) Sep 23, 2019
Statin Immuno-Metabolomics in Asthma (part V) Metabolomics: FAIR Assessment of NIH Common Fund Resources with C2M2
maybe (0.50) no (0.00) yes (1.00)   yesbut (0.75) yes (1.00) no (0.00) yes (1.00) no (0.00) yes (1.00) yesbut (0.75) nobut (0.25) no (0.00) no (0.00) no (0.00) no (0.00) no (0.00) yes (1.00) Sep 23, 2019
Metabolomics Involved in Early-Life Single Pulse Antibiotic Exposures - Serum (part II) Metabolomics: FAIR Assessment of NIH Common Fund Resources with C2M2
maybe (0.50) no (0.00) yes (1.00)   yesbut (0.75) yes (1.00) no (0.00) yes (1.00) no (0.00) yes (1.00) yesbut (0.75) nobut (0.25) no (0.00) no (0.00) no (0.00) no (0.00) no (0.00) yes (1.00) Sep 23, 2019
Minimal change disease and focal segmental sclerosis in urine Metabolomics: FAIR Assessment of NIH Common Fund Resources with C2M2
maybe (0.50) no (0.00) yes (1.00)   yesbut (0.75) yes (1.00) no (0.00) yes (1.00) no (0.00) yes (1.00) yesbut (0.75) nobut (0.25) no (0.00) no (0.00) no (0.00) no (0.00) no (0.00) yes (1.00) Sep 23, 2019
Metabolomics of aged iPSC Metabolomics: FAIR Assessment of NIH Common Fund Resources with C2M2
maybe (0.50) no (0.00) yes (1.00)   yesbut (0.75) yes (1.00) no (0.00) yes (1.00) no (0.00) yes (1.00) yesbut (0.75) nobut (0.25) no (0.00) no (0.00) no (0.00) no (0.00) no (0.00) yes (1.00) Sep 23, 2019
Identification of altered metabolic pathways in Alzheimer's disease, mild cognitive impairment and cognitively normals using Metabolomics (CSF) Metabolomics: FAIR Assessment of NIH Common Fund Resources with C2M2
maybe (0.50) no (0.00) yes (1.00)   yesbut (0.75) yes (1.00) no (0.00) yes (1.00) no (0.00) yes (1.00) yesbut (0.75) nobut (0.25) no (0.00) no (0.00) no (0.00) no (0.00) no (0.00) yes (1.00) Sep 23, 2019
Presentation of different serum metabolites in trauma patients versus healthy volunteers. Metabolomics: FAIR Assessment of NIH Common Fund Resources with C2M2
maybe (0.50) no (0.00) yes (1.00)   yesbut (0.75) yes (1.00) no (0.00) yes (1.00) no (0.00) yes (1.00) yesbut (0.75) nobut (0.25) no (0.00) no (0.00) no (0.00) no (0.00) no (0.00) yes (1.00) Sep 23, 2019
Metabolomics Involved in Early Life Antibiotic Exposures(EstroSTAT-Liver ) Metabolomics: FAIR Assessment of NIH Common Fund Resources with C2M2
maybe (0.50) no (0.00) yes (1.00)   yesbut (0.75) yes (1.00) no (0.00) yes (1.00) no (0.00) yes (1.00) yesbut (0.75) nobut (0.25) no (0.00) no (0.00) no (0.00) no (0.00) no (0.00) yes (1.00) Sep 23, 2019
TCA Cycle Metabolites of Dietary Salt Effects on Blood Pressure in Human Urine from DASH2 Clinical Trial (part VII) Metabolomics: FAIR Assessment of NIH Common Fund Resources with C2M2
maybe (0.50) no (0.00) yes (1.00)   yesbut (0.75) yes (1.00) no (0.00) yes (1.00) no (0.00) yes (1.00) yesbut (0.75) nobut (0.25) no (0.00) no (0.00) no (0.00) no (0.00) no (0.00) yes (1.00) Sep 23, 2019
Polycystic Ovarian Syndrome(PCOS) metabolomics Metabolomics: FAIR Assessment of NIH Common Fund Resources with C2M2
maybe (0.50) no (0.00) yes (1.00)   yesbut (0.75) yes (1.00) no (0.00) yes (1.00) no (0.00) yes (1.00) yesbut (0.75) nobut (0.25) no (0.00) no (0.00) no (0.00) no (0.00) no (0.00) yes (1.00) Sep 23, 2019